SBFMHealthcare · Drug Manufacturers - Specialty & Generic

SBFM Stock Forecast: Sunshine Biopharma, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$1.06

−1.85% on the day

The 1 Wall Street analysts covering Sunshine Biopharma, Inc. hold a median 12-month price target of $56 — +5183.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 12 Sept 2026 — in the upper half.

Market cap

$4.1M

Ticker Nerd rank

61 / 100

Median analyst target

$56

Analysts covering

Revenue$9.3M−1.6% y/y

Operating income−$1.6M

Net income−$1.6M

Free cash flow−$923K

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−4.5%

−13.8%

YTD

−91.4%

−92.8%

From 52W high

−95.2%

From 52W low

0.0%

$22

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

SBFM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sunshine Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Quality

Growth

Accruals

Issuance

Volatility

Momentum

Value

Size (97): Smaller than most of the companies we track.

Value (3): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SBFM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SBFM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $56Median $56High $56

The green dot is the last close — the median target sits +5183.0% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
8 Oct 2025	Aegis Capital	Reiterates	Buy	$7.00
5 Dec 2024	Aegis Capital	Reiterates	Buy	—
7 Aug 2023	Aegis Capital	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SBFM appears on the weeks it earns a place.

Performance

SBFM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Sunshine Biopharma, Inc. returned −92.8% against +17.5% for the S&P 500, dividends included.

SBFM vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SBFM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Sunshine Biopharma, Inc. (SBFM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.2×
Price / sales: 0.1×
Price / book: 0.1×
EV / EBITDA: 1.9×

Growth & margins

Revenue growth (YoY): −1.6%
Earnings growth (YoY): −1.6%
Gross margin: 26.2%
Operating margin: −17.4%
Net margin: −16.5%

Returns & dividend

Return on equity: −21.9%
Return on assets: −9.9%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sunshine Biopharma, Inc. (SBFM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Sunshine Biopharma, Inc. has a market value of $4.1M and an enterprise value of −$9.2M.
Revenue in the twelve months to 30 June 2026: $35.3M. The latest quarter shrank 1.6% year on year.
Net income over the same four quarters: −$5.8M, a −16.5% net margin.
Free cash flow in the twelve months to 30 June 2026: −$5.5M.
Shares outstanding: 2.4M.
Trailing P/E: 0.2×; forward P/E: 0.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Sunshine Biopharma, Inc. employs 50 people — $707K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

SBFM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
SBFMSunshine Biopharma, Inc.	$4.1M	61
SXTCChina Sxt Pharmaceuticals, Inc.	$3.4M	11
APUSApimeds Pharmaceuticals US, Inc.	$3.2M	9
YCBDcbdMD, Inc.	$5.4M	28
SNOASonoma Pharmaceuticals, Inc.	$6.2M	32
PRFXPRF Technologies Ltd.	$2.6M	4
INMInMed Pharmaceuticals, Inc.	$7.1M	25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sunshine Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SBFM news & analysis

Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

Accesswire · 31 Aug 2026positive

Health Canada approved Sunshine Biopharma's Atenolol tablets in 25mg, 50mg, and 100mg doses for the Canadian market. Atenolol is the generic equivalent of the brand-name drug Tenormin, used for treating and managing cardiovascular conditions.

Why it matters — This regulatory approval expands Sunshine Biopharma's approved product portfolio in the Canadian market, adding a cardiovascular treatment option to its generic and specialty medications.

Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer

Accesswire · 26 Aug 2026positive

Sunshine Biopharma reported that its K1.1 mRNA lipid nanoparticle program demonstrated tumor-suppressing activity as a single agent across multiple in vivo hepatocellular carcinoma models. The company outlined next plans, including combining K1.1 mRNA with a cancer vaccine in non-small cell lung cancer to convert "cold" tumors into "hot" tumors.

Why it matters — SBFM watchers would care because this update highlights progress and next steps in the company's oncology pipeline targeting a tumor suppressor frequently mutated in difficult-to-treat lung, pancreatic, and liver cancers.

Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

Accesswire · 19 Aug 2026positive

Sunshine Biopharma announced Canadian regulatory approval for its generic Enalapril tablets in four dosage strengths (2.5mg, 5mg, 10mg, and 20mg), the generic equivalent of Vasotec. The company expects the tablets to begin shipping to Canadian pharmacies by year-end 2026.

Why it matters — This approval expands Sunshine Biopharma's product portfolio into the large global anti-hypertensive drug market.

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

Accesswire · 7 Aug 2026positive

Sunshine Biopharma announced the launch of its generic Amoxicillin formulation in Canada and has begun shipping the antibiotic to Canadian pharmacies in multiple dosages and strengths. The company stated the global Amoxicillin market is projected to reach approximately $6.4 billion by 2031.

Why it matters — The launch expands Sunshine Biopharma's portfolio of essential prescription medications and adds a new revenue stream in a growing global antibiotics market.

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

Accesswire · 4 Aug 2026positive

Sunshine Biopharma announced Canadian regulatory approval for its generic Dienogest 2mg tablets, the generic equivalent of the brand Visanne, which is first-line therapy for pelvic pain associated with endometriosis. This entry targets the $2.8 billion global dienogest market.

Why it matters — SBFM watchers would care because the approval expands the company's portfolio into the growing endometriosis treatment market, projected to reach $5.2 billion by 2034.

FAQ

Frequently asked questions about SBFM stock

What is the SBFM stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Sunshine Biopharma, Inc. have a median 12-month price target of $56, with estimates ranging from $56 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SBFM stock a buy right now?

Of the 1 analysts covering Sunshine Biopharma, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sunshine Biopharma, Inc. 61 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SBFM?

As at 12 Sept 2026, Sunshine Biopharma, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will SBFM stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +5183.0% from the last close, and Ticker Nerd's factor model ranks Sunshine Biopharma, Inc. 61 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SBFM stock forecast for 2030?

No analyst covering Sunshine Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SBFM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $56 to $56 over the next 12 months.

How has SBFM stock performed over the past year?

Sunshine Biopharma, Inc. returned -92.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sunshine Biopharma, Inc. do?

Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing medicines for oncology, antiviral, and other prescription drug markets.

What is the latest news on SBFM?

The most recent item we track (Accesswire, 31 Aug 2026): "Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions". Health Canada approved Sunshine Biopharma's Atenolol tablets in 25mg, 50mg, and 100mg doses for the Canadian market. Atenolol is the generic equivalent of the brand-name drug Tenormin, used for treating and managing cardiovascular conditions.

Company

About Sunshine Biopharma, Inc.

Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing medicines for oncology, antiviral, and other prescription drug markets. The company’s current business spans prescription generic pharmaceuticals and nonprescription over-the-counter products through its operating subsidiaries, alongside a proprietary drug-development pipeline targeting areas with significant unmet medical need. Its portfolio includes generic prescription medicines available in Canada, science-based nutritional supplements, and research programs centered on small-molecule, mRNA, and protease-inhibitor candidates. Sunshine Biopharma Inc. serves as a diversified life-sciences platform that combines marketed healthcare products with ongoing therapeutic development, giving it a role in both established pharmaceutical distribution and early-stage drug innovation. Headquartered in Fort Lauderdale, Florida, the company operates primarily in the United States and Canada.

CEO Dr. Steve N. Slilaty Ph.D. · 50 employees · United States · https://sunshinebiopharma.com